Trial Results, Foreign Sales Bode Well For Celgene
Celgene (CELG) shows how growth abroad can make up for weakness at home. In its Q3 report, released Oct. 25, the Summit, N.J.-based biomed reported EPS of $1.29 on sales of $1.42 billion -- up 26% and 14%, respectively. Both gauges beat estimates by modest amounts. Celgene also upped its full-year EPS guidance by a nickel. That puts it in a $4.85-$4.90 range, vs. last year's $3.79. Sales of Celgene's bread-and-butter product, cancer treatment
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here